Clinical Trials Logo

Central Nervous System Lymphoma clinical trials

View clinical trials related to Central Nervous System Lymphoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02420795 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: November 3, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to see how well it works in treating patients with non-Hodgkin's lymphoma that has returned after a period of improvement or does not respond to treatment. Akt/ERK inhibitor ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.